We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
NuVasive Porous PEEK Implant OK'd for Use in XLIF Procedure
Read MoreHide Full Article
NuVasive, Inc. recently received the FDA’s 510 (k) clearance for its COHERE Porous PEEK implant to be used in eXtreme Lateral Interbody Fusion (XLIF) surgical spine procedures. The company plans to launch COHERE XLIF in the United States in the second quarter of 2019. Following the news announcement, the share price of NuVasive rose 1.3% to close at $59.02 on Nov 8.
Notably, NuVasive’s Porous PEEK technology offers a three-dimensional architecture in conjunction with PEEK’s radiolucent properties. COHERE XLIF happens to be the first buildout of a Porous PEEK implant by NuVasive and also shows strategic expansion of the company’s Advanced Materials Science technologies into NuVasive’s complementary procedures.
Market Potential
Per a report by Becker’s Spine Review, the global minimally-invasive spine surgery market is expected to see a CAGR of 7.6% between 2017 and 2021. Per a report by Technavio, the global spinal implants market is likely to witness a CAGR of roughly 6% in the 2016-2020 period.
Given the current market potential, we believe the company is on the right track to gain traction. We also believe that an ageing population, unhealthy lifestyle, rising awareness and expenditure in healthcare will continue to drive growth this minimally-invasive spine surgery market.
A Glimpse of the U.S. Spinal Hardware Business
In the recently reported quarter, revenues at the U.S. Spinal Hardware business increased around 7% to $146.1 million, driven by launches of modular 3D printed titanium implants for TLIF and XLIF, Porous PEEK offerings, expanded PLF implant offerings and RELINE Small Stature in the United States. The latest development is expected to boost top-line contributions from the segment.
Share Price Movement
Over the past year, NuVasive has outperformed its industry. The stock has gained 6.3% versus the industry’s 1.2% rise.
Zacks Rank & Key Picks
NuVasive has a Zacks Rank #4 (Sell).
A few better-ranked stocks in the broader medical space are Stryker Corporation (SYK - Free Report) , Masimo Corporation (MASI - Free Report) and Veeva Systems (VEEV - Free Report) .
Masimo’s long-term earnings growth rate is projected at 14.6%. The stock carries a Zacks Rank #2.
Veeva Systems’ long-term earnings growth rate is estimated at 19.3%. The stock carries a Zacks Rank #2.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
NuVasive Porous PEEK Implant OK'd for Use in XLIF Procedure
NuVasive, Inc. recently received the FDA’s 510 (k) clearance for its COHERE Porous PEEK implant to be used in eXtreme Lateral Interbody Fusion (XLIF) surgical spine procedures. The company plans to launch COHERE XLIF in the United States in the second quarter of 2019. Following the news announcement, the share price of NuVasive rose 1.3% to close at $59.02 on Nov 8.
Notably, NuVasive’s Porous PEEK technology offers a three-dimensional architecture in conjunction with PEEK’s radiolucent properties. COHERE XLIF happens to be the first buildout of a Porous PEEK implant by NuVasive and also shows strategic expansion of the company’s Advanced Materials Science technologies into NuVasive’s complementary procedures.
Market Potential
Per a report by Becker’s Spine Review, the global minimally-invasive spine surgery market is expected to see a CAGR of 7.6% between 2017 and 2021. Per a report by Technavio, the global spinal implants market is likely to witness a CAGR of roughly 6% in the 2016-2020 period.
Given the current market potential, we believe the company is on the right track to gain traction. We also believe that an ageing population, unhealthy lifestyle, rising awareness and expenditure in healthcare will continue to drive growth this minimally-invasive spine surgery market.
A Glimpse of the U.S. Spinal Hardware Business
In the recently reported quarter, revenues at the U.S. Spinal Hardware business increased around 7% to $146.1 million, driven by launches of modular 3D printed titanium implants for TLIF and XLIF, Porous PEEK offerings, expanded PLF implant offerings and RELINE Small Stature in the United States. The latest development is expected to boost top-line contributions from the segment.
Share Price Movement
Over the past year, NuVasive has outperformed its industry. The stock has gained 6.3% versus the industry’s 1.2% rise.
Zacks Rank & Key Picks
NuVasive has a Zacks Rank #4 (Sell).
A few better-ranked stocks in the broader medical space are Stryker Corporation (SYK - Free Report) , Masimo Corporation (MASI - Free Report) and Veeva Systems (VEEV - Free Report) .
Stryker has a long-term expected earnings growth rate of 10% and a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Masimo’s long-term earnings growth rate is projected at 14.6%. The stock carries a Zacks Rank #2.
Veeva Systems’ long-term earnings growth rate is estimated at 19.3%. The stock carries a Zacks Rank #2.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>